Document Detail

Thrombosis and intrinsic fibrinolysis in percutaneous transluminal angioplasty.
MedLine Citation:
PMID:  8013675     Owner:  NLM     Status:  MEDLINE    
Coagulation and fibrinolysis were investigated in 14 claudicants undergoing percutaneous transluminal angioplasty (PTA) for femoropopliteal artery lesions. Cross-linked fibrin degradation products (XL-FDP), tissue plasminogen activator (t-PA) antigen, fibrinopeptide A (FPA), and plasminogen activator inhibitor-1 (PAI-1) activity were measured in peripheral blood. XL-FDP and t-PA increased, and FPA and PAI-1 decreased significantly after angioplasty. XL-FDP increased from baseline 266 +/- 72 ng/ml to 481 +/- 239 ng/ml (p < 0.0005) 30 min after PTA, indicating mural thrombus formation in spite of the significant fall in FPA influenced by heparin. A groin haematoma developed after PTA in 4/6 patients, who received more than 5600 IU heparin and in 1/8 patients receiving smaller dosages. The alterations in PAI-1 showed no correlation with those of t-PA, whereas heparin had a sparing effect on PAI-1 consumption. These findings may indicate that PAI-1 acts as a thrombin inhibitor following deep vessel wall injury by angioplasty. In two patients, who had signs of rethrombosis on the next day, residual FPA was relatively high, XL-FDP peaked at 3530 +/- 1170 ng/ml, and t-PA increased by 2.6 +/- 1.0 ng/ml. The corresponding values in patients with an uncomplicated course were 406 +/- 89 ng/ml (p < 0.0001) and 0.1 +/- 0.5 ng/ml (p < 0.02). We conclude that thrombin promotes activation of coagulation and fibrinolysis in femoropopliteal PTA. Instability between these counteracting systems resulting in thrombosis is not prevented by conventional heparin administration at dosages causing bleeding complications.
B Jørgensen; J D Nielsen; P Helligsø; N Baekgaard; M Egeblad
Related Documents :
8025945 - Local intramural drug delivery using an infusion balloon following angioplasty in norma...
12744375 - Intracranial stent placement for the treatment of a carotid-cavernous fistula associate...
9047055 - Incidence and outcome of radial artery occlusion following transradial artery coronary ...
21723065 - The epidemiology of subclavian artery calcification.
3515905 - Jaundice secondary to hepatic artery aneurysm: radiological appearance and clinical fea...
15631995 - Triglycidylamine crosslinking of porcine aortic valve cusps or bovine pericardium resul...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of vascular surgery     Volume:  8     ISSN:  0950-821X     ISO Abbreviation:  Eur J Vasc Surg     Publication Date:  1994 May 
Date Detail:
Created Date:  1994-07-22     Completed Date:  1994-07-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8709440     Medline TA:  Eur J Vasc Surg     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  264-9     Citation Subset:  IM    
Vascular Surgery Unit, Skejby Hospital, Aarhus University Hospital, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Balloon* / adverse effects
Blood Coagulation
Femoral Artery
Fibrin Fibrinogen Degradation Products / analysis
Fibrinopeptide A / analysis
Hematoma / etiology
Heparin / administration & dosage,  adverse effects
Intermittent Claudication / blood,  therapy
Middle Aged
Plasminogen Activator Inhibitor 1 / blood
Popliteal Artery
Thrombosis / blood*,  etiology,  prevention & control
Tissue Plasminogen Activator / blood
Reg. No./Substance:
0/Fibrin Fibrinogen Degradation Products; 0/Plasminogen Activator Inhibitor 1; 25422-31-5/Fibrinopeptide A; 9005-49-6/Heparin; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Human chromosomal centromere (AATGG)n sequence forms stable structures with unusual base pairs.
Next Document:  Experience with pulse-spray technique in peripheral thrombolysis.